Clinical Trial

Tempus Priority Study: A Pan-tumor Observational Study

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
Observational study that will be collecting clinical and molecular health information from cancer patients who have received comprehensive genomic profiling and meet the specific eligibility criteria outlined for each cohort with the goal of conducting research to advance cancer care and create a dataset that furthers cancer research.
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2021-12-16; most recent amendment 2025-05-05.
Status change: Recruiting → Active, Not Recruiting 2024-10-16
Trial Details
NCT Number NCT05179824
Lead Sponsor Tempus AI
Conditions Breast Cancer, Prostate Cancer, Bladder Cancer, Lung Cancer, Brain Cancer, Pancreatic Cancer, Ovarian Cancer, Fallopian Tube Cancer +19 more
Enrollment 1,000 participants
Start Date 2020-10-19
Primary Completion 2026-10-19 (estimated)
Study Completion 2030-10-19 (estimated)
Updated on ClinicalTrials.gov 2025-05-06